The potential hepatoprotective effect of metformin in hepatitis C virus-infected adolescent patients with beta thalassemia major: Randomised clinical trial.

Mona S Abdel Monem Samar F Farid Maggie M Abbassi Ilham Youssry Nevine G Andraues Mohamed Hassany Yasmeen M M Selim Manal H El-Sayed

Published in: International journal of clinical practice (2021)

The use of metformin in HCV-infected β-TM adolescent patients as an adjuvant antioxidant hepatoprotective agent is promising and can improve liver damage.

Keyphrases

hepatitis c virus
clinical trial
young adults
mental health
open label
human immunodeficiency virus
oxidative stress
end stage renal disease
ejection fraction
newly diagnosed
study protocol
early stage
double blind
prognostic factors
phase ii
patient reported outcomes